EXCLUSIVE: ProSomnus Tells Benzinga Co. Updated Clinical Trial Data Indicates Precision Oral Appliance Therapy Co's Devices Is Non-Inferior To CPAP Therapy for The Treatment Of Moderate To Severe Obstructive Sleep Apnea
Portfolio Pulse from Benzinga Newsdesk
ProSomnus has updated clinical trial data indicating that its precision oral appliance therapy devices are non-inferior to CPAP therapy for the treatment of moderate to severe obstructive sleep apnea (OSA).
August 23, 2023 | 11:30 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Benzinga Co. reported on ProSomnus' updated clinical trial data, which could potentially impact its reputation as a reliable source of financial news.
Benzinga Co. is the source of the news, but the news is about ProSomnus. The impact on Benzinga Co. is neutral as it is merely reporting the news, but its reputation could be affected depending on the accuracy of the report.
CONFIDENCE 80
IMPORTANCE 50
RELEVANCE 50